VTRS · 10-Q · 2026Q3 · Full report
Other Income (Expense), Net
Viatris Inc · 2026-11-05 · Importance 63 · Surprise 64 · Matches filing data
Other expense, net fell by $481.6 million to $18.3 million for the nine months ended September 30, 2026, from $499.9 million in the prior-year period. The primary driver was the absence of the prior-year $499.8 million loss from fair-value changes in Biocon Biologics CCPS, alongside a $65.2 million reduction in divestiture losses. The improvement was partly offset by $33.2 million less TSA income and a $36.0 million loss from fair-value changes and the subsequent sale of Biocon equity shares in 2026.
Key facts
- Viatris' prior-year other expense included a $499.8 million loss from changes in the fair value of Biocon Biologics CCPS, and the loss on divestitures decreased by $65.2 million. source
- Viatris' interest expense for the nine months ended September 30, 2026 was $353.2 million, compared with $351.7 million for the nine months ended September 30, 2025. source
- The decrease in third-quarter other expense primarily reflected a $100.0 million prior-year loss from fair-value changes in Biocon Biologics CCPS, partly offset by a $27.4 million current-year loss from fair-value changes and subsequent sale of Biocon equity shares. source
- Viatris recognized pretax losses from changes in fair value and subsequent sale of Biocon equity shares of approximately $27.4 million for the three months and $36.0 million for the nine months ended September 30, 2026. source
- Viatris recognized $88.2 million of contingent consideration adjustment losses for the nine months ended September 30, 2026, compared with a $150.3 million gain in the prior-year period. source
- Third-quarter 2026 other expense, net, was $21.2 million, down $45.9 million from $67.1 million in the prior-year quarter. source
- Viatris' other expense, net, was $18.3 million for the nine months ended September 30, 2026, compared with $499.9 million for the nine months ended September 30, 2025, a decrease of $481.6 million. source
- Viatris' other expense decrease was partially offset by a $33.2 million decrease in TSA income and a $36.0 million current-year loss from changes in fair value and subsequent sale of Biocon equity shares. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| net_income | positive | realized | +1.8% | Viatris' prior-year other expense included a $499.8 million loss from changes in the fair value of Biocon Biologics CCPS, and the loss on… |